11月13日，康希诺生物盘中下跌4.02%，报24.82港元，成交额3045.23万港元。
近阶段公司披露的新增公开信息主要包括：10月股份变动月报显示，H股与A股数量均与上月一致，报告期内无新增发行、回购或注销；同时，公司完成持续督导保荐代表人变更，由王天祺接替徐峰林，与焦延延共同履职。
此前公司三季报显示，前三季度实现营收8.82亿元，同比增长27.40%，归母净利润1629.13万元，同比增长12.82%。当前股价回落，公开消息面上未见更强新增催化，市场仍在消化既有业绩与行业情绪变化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.